Abstract
Neuropsychiatric pathologies, including neurodegenerative diseases and neurodevelopmental syndromes, are frequently associated with dysregulation of various essential cellular mechanisms, such as transcription, mitochondrial respiration and protein degradation. In these complex scenarios, it is difficult to pinpoint the specific molecular dysfunction that initiated the pathology or that led to the fatal cascade of events that ends with the death of the neuron. Among the possible original factors, epigenetic dysregulation has attracted special attention. This review focuses on two highly related epigenetic factors that are directly involved in a number of neurological disorders, the lysine acetyltransferases CREB-binding protein (CBP) and E1A-associated protein p300 (p300). We first comment on the role of chromatin acetylation and the enzymes that control it, particularly CBP and p300, in neuronal plasticity and cognition. Next, we describe the involvement of these proteins in intellectual disability and in different neurodegenerative diseases. Finally, we discuss the potential of ameliorative strategies targeting CBP/p300 for the treatment of these disorders.
Keywords: Histone acetylation, CBP, p300, Rubinstein-Taybi syndrome, Huntington’s disease, Alzheimer’s disease, HDACi, KATe, KATi.
Current Pharmaceutical Design
Title:Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Volume: 19 Issue: 28
Author(s): Luis M. Valor, Jose Viosca, Jose P. Lopez-Atalaya and Angel Barco
Affiliation:
Keywords: Histone acetylation, CBP, p300, Rubinstein-Taybi syndrome, Huntington’s disease, Alzheimer’s disease, HDACi, KATe, KATi.
Abstract: Neuropsychiatric pathologies, including neurodegenerative diseases and neurodevelopmental syndromes, are frequently associated with dysregulation of various essential cellular mechanisms, such as transcription, mitochondrial respiration and protein degradation. In these complex scenarios, it is difficult to pinpoint the specific molecular dysfunction that initiated the pathology or that led to the fatal cascade of events that ends with the death of the neuron. Among the possible original factors, epigenetic dysregulation has attracted special attention. This review focuses on two highly related epigenetic factors that are directly involved in a number of neurological disorders, the lysine acetyltransferases CREB-binding protein (CBP) and E1A-associated protein p300 (p300). We first comment on the role of chromatin acetylation and the enzymes that control it, particularly CBP and p300, in neuronal plasticity and cognition. Next, we describe the involvement of these proteins in intellectual disability and in different neurodegenerative diseases. Finally, we discuss the potential of ameliorative strategies targeting CBP/p300 for the treatment of these disorders.
Export Options
About this article
Cite this article as:
Valor M. Luis, Viosca Jose, Lopez-Atalaya P. Jose and Barco Angel, Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders, Current Pharmaceutical Design 2013; 19 (28) . https://dx.doi.org/10.2174/13816128113199990382
DOI https://dx.doi.org/10.2174/13816128113199990382 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Motor and Non-Motor Features of Parkinson’s Disease – A Review of Clinical and Experimental Studies
CNS & Neurological Disorders - Drug Targets Synthesis, Antioxidant and Anti-inflammatory Properties of an Apocynin- Derived Dihydrocoumarin
Medicinal Chemistry Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug
Current Topics in Medicinal Chemistry Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration
Current Neuropharmacology Future Therapeutic Directions: New Medications and Insulin Delivery in a Changing World for Effective Diabetes Management
Current Drug Discovery Technologies Natural Sirtuin Modulators in Drug Discovery: A Review (2010 -2020)
Current Medicinal Chemistry Pharmacogenetics in Affective Disorders: A Drug Response Approach
Current Pharmacogenomics A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine Mitochondrial Biology and Neurological Diseases
Current Neuropharmacology Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Simple Choline Esters as Potential Anti-Alzheimer Agents
Current Pharmaceutical Design Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Chelating Agents for Neurodegenerative Diseases
Current Medicinal Chemistry Position Based Nucleotide Analysis of miR168 Family in Higher Plants and its Targets in Mammalian Transcripts
MicroRNA The Role of Mitochondrial Genes in Neurodegenerative Disorders
Current Neuropharmacology Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research Dimerization and Ion Binding Properties of S100P Protein
Protein & Peptide Letters